Chelation therapy to remove potentially toxic levels of lead was not associated with a reduction in CV events in post-MI patients with diabetes in the TACT2 trial.
Three former executives of medical device company Magellan Diagnostics concealed a malfunction in the company’s lead-testing devices that caused tests to underestimate the level of lead in people s blood, U.S. prosecutors in Boston said in announcing criminal charges on Wednesday.